EUCTR2005-006082-14-IT进行中（未招募）不适用
A Multi-center, Randomized, Double-blind, Two-Arm, Phase III Study in Patients with Untreated Stage III Unresectable or IV Melanoma Receiving Dacarbazine Plus 10mg/kg of Ipilimumab MDX-010 vs. Dacarbazine With Placebo - CA184-024
Bristol Myers Squibb S.r.L.0 个研究点目标入组 500 人开始时间: 2006年11月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed written informed consent 1 Willing and able to give written informed consent; Target population 2 Histologic diagnosis of malignant melanoma; 3 Untreated unresectable Stage III melanoma with N3 macroscopic lymph nodes or in-transit/satellite metastases or Stage IV melanoma AJCC 2001 note that prior adjuvant melanoma therapy is permitted e.g., IFN therapy ; 4 Measurable/evaluable disease as per modified WHO criteria , within 28 days of first dose of study drug; 5 Life expectancy of 8805; 16 weeks; 6 ECOG performance status of 0 or 1 see Appendix 3 ; 7 Have the complete set of baseline i.e., Screening digital images of lesions and radiographic images, including, but not limited to brain, chest, abdomen pelvis and bone scans. All images must be of adequate quality; 8 Required values for initial laboratory tests WBC 8805; 2500/uL ANC 8805; 1000/uL Platelets 8805; 75 x 103/uL Hemoglobin 8805; 9 g/dL Creatinine 8804; 2.5x ULN AST 8804; 3 x ULN for patients without liver metastasis 8804; 5 x ULN for patients with liver metastasis Bilirubin 8804; 3x ULN, except patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg/dL; 9 Negative Screening tests for HIV, HepB, and HepC. If positive results are not indicative of true active or chronic infection, the patient can enter the study after discussion and agreement between the Investigator and the CRO Medical Monitor; 10 Accessible for treatment and Follow-Up; Age and Sex 11 Men and women 18 years of age or, 8805; 16, if allowable per local regulatory authority .
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Sex and Reproductive Status 1 WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study. 2 Women who are pregnant or breastfeeding 3 Women with a positive pregnancy test on enrollment or prior to study drug administration. 4 Sexually active fertile men whose partners are WOCBP, unless using an adequate method of birth control Medical History and Concurrent Diseases 5 Evidence of brain metastases on brain imaging i.e., MRI or contrast CT ; 6 Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix; 7 Primary ocular or mucosal melanoma; 8 Autoimmune disease Patients with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn s disease are excluded from this study as are patients with a history of symptomatic disease e.g., rheumatoid arthritis, systemic progressive sclerosis scleroderma , Systemic Lupus Erythematosus, autoimmune vasculitis e.g., Wegener s Granulomatosis ; 9 Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea; Prohibited Therapies and/or Medications 10 Prior or concomitant therapy with any anti-cancer agent, immunosuppressive agents, surgery or radiotherapy except as defined in Sections 6.2.8.3 and 6.2.8.4 ; other investigational anti-cancer therapies, or chronic use of systemic corticosteroids used in the management of cancer or non-cancer-related illnesses . Prior adjuvant therapy is not exclusionary; 11 Any non-oncology vaccine therapy used for prevention of infectious diseases for up to 4 weeks prior to or after any dose of ipilimumab or dacarbazine ; 12 Prior treatment with a CD137 agonist or CTLA-4 inhibitor or agonist; 13 Previous participation in another ipilimumab MDX-010 clinical trial; 14 Treatment with other investigational products within the last 4 weeks prior to randomization into this study;
研究者
相似试验
已完成
不适用
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaPER-056-07BRISTOL MYERS SQUIBB PERU S.A.,
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients withUntreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.Revised Protocol 04, incorporating Administrative Letter 01, Administrative Letter 02, Administrative Letter 03, Amendment 02, Amendment 06 and Amendment 07.Stage III (Unresectable) or IV MelanomaEUCTR2005-006082-14-ATBristol-Myers Squibb International Corporation500
进行中（未招募）
不适用
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaStage III (Unresectable) or IV MelanomaEUCTR2005-006082-14-DEBristol-Myers Squibb International Corporation500
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients withUntreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.Revised Protocol 03, incorporating Administrative Letter 01, Administrative Letter 02, Amendment 02, and Amendment 06Stage III (Unresectable) or IV MelanomaEUCTR2005-006082-14-PTBristol-Myers Squibb International Corporation500
已完成
3 期
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebomelanosarcomaskincancer10040900NL-OMON34151Bristol-Myers Squibb12